To assess effectiveness and safety of Foley catheter versus vaginal misoprostol for term induction of labor.
Introduction
In developed countries around 20-30% of all births are induced. [1] [2] [3] Although labor induction is a common obstetric procedure, it is associated with a higher risk of complications compared with spontaneous labor. In spite of numerous reports comparing the safety and efficacy of different induction techniques, there is still no consensus on which method is preferable. [4] [5] [6] [7] Mechanical methods, with Foley catheter being the most commonly used currently, are amongst the oldest methods of labor induction. Foley catheters work through mechanical dilation, resulting in the release of natural prostaglandins from the cervix. 8 In recent decades mechanical methods have largely been replaced by pharmacological methods, such as prostaglandin E2 and prostaglandin E1 analogues. Their mechanism of action is twofold. Prostaglandins ripen the cervix directly by enzymatic collagen degradation and increase of water content in the extracellular matrix. Indirectly, they stimulate the myometrium and thereby induce contractions. 9, 10 Although Foley catheters have been partly been replaced by prostaglandins, they have several potential advantages over pharmacological methods. They are relatively inexpensive, easy to store, and easy to remove when necessary. We recently showed that, compared to intravaginal prostaglandin E2 gel, use of a Foley catheter for the induction of labor results in similar cesarean delivery rates with fewer maternal and neonatal side-effects. 11 Meta-analysis revealed a lower rate of hyperstimulation and a reduction of postpartum hemorrhage. 11 Misoprostol, a prostaglandin E1 analogue, is one of the prostaglandins most frequently used for labor induction worldwide, mainly due to its low cost and easy storage. 12 Although not FDA approved for induction of labor, misoprostol is recommended by the American College of Obstetricians and Gynecologists (ACOG), The British Royal college of Obstetricians and Gynecologists (RCOG), as well as the International Federation of Gynecology and Obstetrics (FIGO) and the World Health Organization (WHO). 4, 5, 13 In the Netherlands, however, this pharmacological agent is rarely used for cervical ripening. 6 Current literature comparing Foley catheter to misoprostol shows similar success rates of labor induction, with fewer cases of uterine hyperstimulation with and without fetal heart rate changes, 9, 14, 15 , and a comparable cesarean section rate when a Foley catheter is used. 14 However, randomized controlled trials are underpowered to investigate the estimators of interest, and meta-analyses are performed with studies using different dosing regimens of misoprostol, and are therefore not generally applicable. Different prostaglandin analogues and dosing regimens seem to have different side effects.
Therefore, in this PROBAAT-M trial, parallel to our main study the PROBAAT trial, we compared the effectiveness and safety of Foley catheter to 25 microgram (mcg) vaginal misoprostol. Additionally we performed a meta-analysis of this comparison to gather as much information as possible on the effectiveness and safety of Foley catheters versus 25 mcg misoprostol for term cervical ripening and labor induction.
Methods

Trial design
This was an open-label randomized controlled trial comparing Foley catheter with 25 mcg vaginal misoprostol for induction of labor at term in women with an unfavorable cervix. This pilot study was conducted parallel to the main PROBAAT study. As vaginal prostaglandin E2 gel was the most frequently used method for induction of labor in women with an unfavorable cervix, the goal of the main study was to investigate the effectiveness and safety of Foley catheter versus prostaglandin E2 gel. 11 We performed the current study parallel to the main PROBAAT study, and according to a parallel protocol (PROBAAT-M) together with a study comparing 10mg slow release vaginal prostaglandin E2 inserts (PROBAAT P). The results of the latter study will be published separately. At the time of the study, vaginal misoprostol was only used in four participating hospitals in the Netherlands. The protocol was approved by the Ethics committee of the Academic Medical Centre Amsterdam (MEC 08/310), and the institutional review boards of participating hospitals. The trial was registered with the Netherlands Trial Register (NTR 1646).
Participants
Women over 18 years of age with a term pregnancy and an unfavorable cervix (Bishop score <6), requiring induction of labor were eligible for the study. Exclusion criteria were prior cesarean delivery, non-vertex presentation of the fetus, ruptured membranes, a hypersensitivity for one of the products used for induction, or a lethal congenital anomaly of the fetus.
Outcomes
The main outcome was cesarean delivery. Secondary outcomes included maternal and neonatal morbidity and time from the start of induction to birth. These are described in detail in the main trial.
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Sample Size
As described above, this pilot study was conducted parallel to the PROBAAT study, within the same timeframe. We randomized for the comparison Foley catheter versus all pharmacological methods until power in the prostaglandin E2 gel trial was reached. We did not calculate a separate sample size for the current study. The study was ended in May 2010 at the time the main study's power was reached. No analysis of data was done prior to the end of the study.
Randomization and blinding
Women were informed about the study by their obstetrician, when the need for induction of labor occurred. After informed consent, women were enrolled by the attending physician, midwife or research nurse at the labor ward on the day of induction. Randomization occurred through a webbased randomization program. The randomization sequence was computer generated, and was composed out of variable blocks of 2 and 4, which could not be viewed by the recruiter, nor by the trial-coordinator when the trial was ongoing. Women were randomized between Foley catheter and vaginal misoprostol in a 1:1 ratio. Due to the nature of the intervention, neither the caregiver, nor the patient were blinded.
Intervention
The interventions are described in detail in the main study. 11 In short, a Foley catheter filled with 30 cc sterile saline or water was introduced transcervically in women in the Foley catheter group. The protocol advised to examine women at the same four hour intervals as women in the misoprostol group.
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In the misoprostol group women were treated with 25 microgram (mcg) tablets, inserted into the posterior vaginal fornix every four hours, with a maximum of 3 doses in 24 hours. Doses were withheld when there were 3 or more contractions in 10 minutes, or in case of a non--reassuring fetal heart rate tracing. If upon examination the Bishop score was ≥6, amniotomy was performed, and oxytocin was started according to local protocol if contractions or progress were deemed inadequate.
Statistical Methods
Data were analyzed according to the intention--to--treat principle. Normally distributed data are presented as means with standard deviation; skewed distributions are presented as medians with interquartile ranges (IQR). For categorical data the treatment effect is presented as relative risks (RR) with 95% confidence intervals. P--values were calculated using the χ 2 test, in case the expected cell count was <5 Fisher's exact test was used. For continuous data with a non--normal distribution the Mann--Whitney U test was used. For time to delivery data Kaplan--Meier survival curves were constructed and Log--rank tests and according p--values calculated. Further details are described in detail in the main article.
11
Meta--analysis
We searched the Cochrane collaboration's trial registry from January 1966 to January 2013, while Medline and EMBASE were searched from January 2012 till January 2013, the latter because the Cochrane collaboration's trial registry is updated only 4 times a year. Our search was expanded till 2013 to include articles that are already online but not yet published in print. We used the following terms: (Balloon Dilation OR mechanical methods OR mechanical method OR mechanical dilation OR mechanical dilatation OR mechanical dilations OR mechanical dilatations OR balloon OR foley* OR Catheterization OR Catheterisation OR catheter OR catheters OR catheter*) AND (prostaglandin E1 OR PGE1 OR PGE--1 OR misoprostol OR Abortifacient Agents, Nonsteroidal OR ((Nonsteroidal OR "Non--Steroidal") AND Abortifacient) OR Alprostadil OR Prostaglandin E1alpha OR PGE1alpha OR Prostaglandin E1 OR Lipo--PGE1 OR Lipo PGE1 OR Edex OR Viridal OR Prostavasin OR Prostin VR OR Minprog OR Prostine VR OR Vasaprostan OR Caverject OR Sugiran) All randomized clinical trials comparing Foley catheter to 25 mcg vaginal misoprostol for cervical ripening in singleton pregnancies with a viable fetus in vertex presentation, intact membranes and an unfavorable cervix were eligible. Two reviewers (MJ, ME) independently assessed all studies identified by the search for inclusion. Any disagreement was resolved through discussion or, in case of persisting disagreement, a third author (KB) was consulted. The treatment outcome measures sought, were all outcome measures reported in the PROBAAT--M--trial, cesarean delivery being the primary outcome measure. Studies were excluded if they did not report any of the predefined outcome measures. We attempted to contact the authors of studies that were only reported as abstract or did not report the predefined outcome measures. Two review authors (MJ, ME) independently assessed the methodological quality of the studies, using the Cochrane Collaboration's tool for methodological assessment of studies. 16 None of the trials were excluded on the basis of methodology assessment, but sensitivity analysis was carried out excluding poor quality studies. Publication bias was investigated through visual inspection of funnel plots, which were constructed for all outcomes with ten or more studies. All statistical analyses were performed in Review Manager software. 17 We present the results as summary risk ratio (RR) with 95% confidence intervals (CIs), as we sought only dichotomous data. We assessed heterogeneity in each meta-analysis using the T², I², and Χ² statistics. Heterogeneity was regarded as substantial if I² >30% and either T² >0, or the P value <0.10 in the Chi² test for heterogeneity. We used a fixed-effect model for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect. When statistical heterogeneity was substantial, we used a random-effects model for pooling.
We performed a subgroup analysis of studies in which Foley catheters were compared to 25 mcg vaginal misoprostol every 4 hours, as this is the dose that was used in the current study, and has been recommended before by FIGO. 13 Statistical significance was defined as a p-value <0.05.
Results
Trial results
Between February 2009 and May 2010 we included 120 women in four centers, of which 56 were allocated to the Foley catheter group and 64 to the misoprostol group (Figure 1 ). Baseline characteristics were much the same. (Table 1 Significantly more cesarean deliveries were performed for failure to progress in the first stage of labor in the Foley catheter group. There was a non-significant decrease in vaginal instrumental deliveries in the Foley catheter. (Table 2 ) The median time from the start of induction to birth was longer in the Foley catheter group. Maternal and neonatal outcomes are presented in Table 3 . No significant differences between the treatment groups were noted for these outcomes. No serious adverse events were recorded. 
Meta-analysis results
We identified 102 citations in the Cochrane collaboration's trial registry, 17 in Medline and 46 in EMBASE. After removal of duplications 144 citations remained. Of these, 103 were excluded based on the title, because they either did not investigate labor induction or used other induction agents.
Of the 41 Abstracts reviewed, 27 more studies were excluded, because they applied a different dose or route of administration of misoprostol. The full text articles of the remaining 15 were screened, and another three papers were excluded because they did not fulfill our inclusion criteria: one was a crossover trial and one included women with a cesarean scar (although this was an exclusion criterion of the trial itself), and one paper was a duplicate. (Figure 2) We excluded three more trials, as after contacting the authors of the three trials data were still not available. [18] [19] [20] Counting the current trial, ten trials were included in this meta-analysis. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The overall methodological quality was reasonable for seven trials, and poor for three. (Table 4) Six studies investigated 25 mcg vaginal misoprostol administered every four hours. In one study misoprostol was administered every three hours, and in three studies every six hours. (Table 4) The overall cesarean delivery rate did not differ statistically between the groups, nor did the risk of vaginal instrumental delivery. Oxytocin was used more often in the Foley catheter group. Hyperstimulation, both without and with non-reassuring fetal heart rate tracing, was seen less often in the Foley catheter group. We did not find any significant differences in the other outcomes. (Table  5) The subgroup analysis of studies comparing Foley catheter with 25 mcg misoprostol every four hours including data of the current trial showed comparable cesarean delivery rates, a reduction in vaginal instrumental deliveries, a reduction in hyperstimulation with fetal heart rate changes, significantly more oxytocin use in the Foley catheter group (figure 3a and 3b), and no differences in the remaining maternal and neonatal outcomes (data not shown). 22, 23, 25, 29, 30 As only the outcome 'cesarean delivery' for the comparison Foley catheter versus 25 mcg vaginal misoprostol-all dosing schedules, was the result of meta-analysis of 10 or more studies, this is the only Reporting bias: unclear *GA= Gestational age. †BS = Bishop Score. ‡mcg = microgram. §cc=milliliter. ǁITT=intention-to-treat outcome a funnel plot was constructed for. (Appendix 1) Visual inspection of the plot does not show asymmetry. Other outcomes were all based on less than ten studies, and therefore the power of the funnel plot asymmetry test would be too small. Publication bias in this case can unfortunately not be excluded, also on the basis of funnel plots. Sensitivity analysis, excluding poor quality studies, did not change the conclusions, however the relative risk for cesarean delivery rate changed direction (RR 0.98, 95%CI 0.66-1.46). 
Discussion
In this trial comparing Foley catheter to 25 mcg vaginal misoprostol, we found that cesarean delivery rates and vaginal instrumental deliveries were not different, but more cesarean deliveries were performed for failure to progress in the first stage after induction with a Foley catheter. When using a Foley catheter the time from start of induction to birth was significantly longer, and oxytocin augmentation was more often required. Maternal and neonatal secondary outcomes, including post partum hemorrhage and pH <7.10, did not differ significantly between the groups. Although we did not find any differences in primary and secondary outcomes these results should be interpreted cautiously, due to the small numbers. While the numbers were small, our trial was a valuable contribution to meta--analysis. In meta--analysis we found that Foley catheter compared to 4 hourly vaginal administration of 25 mcg misoprostol yields comparable cesarean delivery rates, reduced rates of vaginal instrumental deliveries and of hyperstimulation, and an increase in oxytocin use. To our knowledge, this is the first meta--analysis that separately compares the most prevailing dose of misoprostol, 25 mcg vaginally, to Foley catheter. Previous reviews comparing Foley catheters to misoprostol included different doses and dosing schedules. 14, 31 As different dosing regimens are likely to affect the efficacy and safety of the induction agent, it is important to review them separately.
Figure 3a. Meta--analysis Foley catheter versus 25 mcg vaginal misoprostol/4 hours with random effect
Our meta--analysis included 10 studies comparing Foley catheter to 25 mcg vaginal misoprostol. Six studies, with a total of 628 participants, dosed the misoprostol every four hours. In these six trials misoprostol was compared to a Foley catheter filled with 30 cc Foley catheter in three studies, 35 cc in one study, and 50cc in two studies. Even though there is some evidence that a higher volume in the Foley balloon is more effective, 32, 33 we have chosen to include all six studies in our subgroup analysis. Despite this, the total number of women is still too small to make definitive conclusions about safety of the two methods. Excluding the studies with a higher balloon volume did not change our conclusions regarding the primary outcome. While the total cesarean delivery rate in the current trial did not differ significantly, the rate of cesarean deliveries for failure to progress was higher in the Foley catheter group, with a very wide confidence interval (1.01-20.6). In the protocol, we did not define failure to progress in the first stage, as there is no commonly accepted definition of failure to progress in the first stage after induction of labor. A recent study, which aimed to find an objective definition of failed induction or failure to progress in the first stage of labour, concludes that it is reasonable to avoid deeming labor induction a failure in the latent phase until oxytocin has been administered for at least 12 hours after membrane rupture. Additionally, 40% of women with a latent phase after membrane rupture longer than 12 hours deliver vaginally if allowed longer oxytocin infusion.
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Figure 3b. Meta-analysis Foley catheter versus 25 mcg vaginal misoprostol/4 hours with Fixed effect
When reviewing the cases of women undergoing cesarean delivery due to failure to progress in the first stage, we found that in three out of the eight cases, the cesarean delivery was performed within 12 hours from rupture of membranes. Our hypothesis is that if more time was allowed, these women might have had the opportunity to deliver vaginally. Oxytocin is used significantly more often when a Foley catheter is employed. This indicates that Foley catheter does not primarily cause contractions, but merely ripens the cervix. Hereby Foley catheters enable the separation of cervical ripening and actual labor induction. This could be an advantage, especially in case of induction with intrauterine growth restriction or oligohydramnios, where the fetus may have decreased tolerability for contractions. Cervical ripening before induction of contractions could also decrease the need for fetal monitoring during ripening, which can enable outpatient use and consequent cost reduction of labor induction. Several researchers have studied inpatient versus outpatient cervical ripening using a Foley catheter. No significant differences were found in mode of delivery, and maternal and neonatal morbidity comparing in and outpatient ripening. However, a significant decrease in hospitalization time and costs was found when ripening was applied in an outpatient setting. 35, 36 Adequately powered studies, are needed to confirm the safety of outpatient Foley catheter use for cervical ripening.
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The use of misoprostol in women with a prior cesarean delivery has been questioned, because several case reports, and a randomized controlled trial, which was stopped prematurely due to safety concerns, suggest an increased risk of uterine rupture. 37--41 Foley catheters do not seem to cause contractions during the ripening phase, and could therefore be a good alternative for labor induction in women with a history of cesarean delivery. Although retrospective data on Foley catheter use in these women suggest that it is safe, 42, 43 prospective data on the comparison of methods for cervical ripening in this group of women are scarce. Therefore, we are currently investigating Foley catheter for induction in women with a prior cesarean delivery in a large prospective cohort (PROBAAT--S study).
In conclusion, Foley catheter compared to 25 mcg vaginal misoprostol administered every 4 hours, has comparable effectiveness on vaginal delivery rates, but a longer induction to delivery interval. However, there is a lower risk of hyperstimulation with fetal heart rate changes and a lower risk of vaginal instrumental delivery, which gives the Foley catheter potential benefits.
